白血病
药物输送
药代动力学
药品
免疫疗法
不利影响
药理学
化疗
恶性肿瘤
肿瘤科
癌症研究
医学
化学
内科学
免疫学
免疫系统
有机化学
作者
Tianyuan Ci,Wentao Zhang,Yingyu Qiao,Huangjuan Li,Jing Zang,Hongjun Li,Nianping Feng,Zhen Gu
摘要
Leukemia is a hematological malignancy associated with the uncontrolled proliferation of mutant progenitors, suppressing the production of normal blood cells. Current treatments, including chemotherapy, radiotherapy, and immunotherapy, still lead to unsatisfactory results with a 5 year survival rate of only 30-50%. The poor prognosis is related to both disease relapse and treatment-associated toxicity. Delivery strategies can improve the in vivo pharmacokinetics of drugs, navigating the therapeutics to target cells or the tumor microenvironment and reversing drug resistance, which maximizes tumor elimination and alleviates systematic adverse effects. This review discusses available FDA-approved anti-leukemia drugs and therapies with a focus on the advances in the development of anti-leukemia drug delivery systems. Additionally, challenges in clinical translation of the delivery strategies and future research opportunities in leukemia treatment are also included.
科研通智能强力驱动
Strongly Powered by AbleSci AI